Reactions 1680, p235 - 2 Dec 2017 causality score was 1 (possibly treatment related). CAse 8: A 61-year-old man, who was diagnosed with HCV- infection and cirrhosis received treatment with sofosbuvir and ribavirin. After 1.9 weeks of the treatment, he developed Various toxicities: 16 case reports * hyperbilirubinaemia. Later, he was hospitalised due to In a observational cohort study, 16 patients (5 women and – portosystemic encephalopathy. Her hyperbilirubinaemia 11 men) aged 40 79 years were described, who developed improved after ribavirin dosage reduction and portosystemic various toxicities during treatment with sofosbuvir, simeprevir, encephalopathy improved with unspecified medications. The ribavirin or peginterferon-alfa [dosages and routes not stated]. total duration of treatment was 24 weeks. The causality score Out of these 16 patients, one patient died of multiple organ was 3 (likely treatment related). failure. Case 9: A 67-year-old man, who was diagnosed with HCV- Case 1: A 78-year-old woman, who was diagnosed with infection received treatment with sofosbuvir and ribavirin. HCV-infection, lymphoma and cirrhosis received treatment After 8 weeks of the treatment, he developed anaemia and with sofosbuvir and ribavirin. After 2.9 weeks of the treatment, required hospitalised and blood transfusion. Later, he she developed variceal bleeding and was
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera